137 related articles for article (PubMed ID: 38241700)
1. Targeting the Epigenetic Reader ENL Inhibits Super-Enhancer-Driven Oncogenic Transcription and Synergizes with BET Inhibition to Suppress Tumor Progression.
Chen Y; Ying Y; Ma W; Ma H; Shi L; Gao X; Jia M; Li M; Song X; Kong W; Chen W; Zheng X; Muluh TA; Wang X; Wang M; Shu XS
Cancer Res; 2024 Apr; 84(8):1237-1251. PubMed ID: 38241700
[TBL] [Abstract][Full Text] [Related]
2. ENL links histone acetylation to oncogenic gene expression in acute myeloid leukaemia.
Wan L; Wen H; Li Y; Lyu J; Xi Y; Hoshii T; Joseph JK; Wang X; Loh YE; Erb MA; Souza AL; Bradner JE; Shen L; Li W; Li H; Allis CD; Armstrong SA; Shi X
Nature; 2017 Mar; 543(7644):265-269. PubMed ID: 28241141
[TBL] [Abstract][Full Text] [Related]
3. Targeting Oncogenic Super Enhancers in MYC-Dependent AML Using a Small Molecule Activator of NR4A Nuclear Receptors.
Call SG; Duren RP; Panigrahi AK; Nguyen L; Freire PR; Grimm SL; Coarfa C; Conneely OM
Sci Rep; 2020 Feb; 10(1):2851. PubMed ID: 32071334
[TBL] [Abstract][Full Text] [Related]
4. miR-766-5p Targets Super-Enhancers by Downregulating CBP and BRD4.
Gen Y; Muramatsu T; Inoue J; Inazawa J
Cancer Res; 2021 Oct; 81(20):5190-5201. PubMed ID: 34353856
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic super-enhancers in cancer: mechanisms and therapeutic targets.
Bacabac M; Xu W
Cancer Metastasis Rev; 2023 Jun; 42(2):471-480. PubMed ID: 37059907
[TBL] [Abstract][Full Text] [Related]
6. Recognition of histone acetylation by the GAS41 YEATS domain promotes H2A.Z deposition in non-small cell lung cancer.
Hsu CC; Shi J; Yuan C; Zhao D; Jiang S; Lyu J; Wang X; Li H; Wen H; Li W; Shi X
Genes Dev; 2018 Jan; 32(1):58-69. PubMed ID: 29437725
[TBL] [Abstract][Full Text] [Related]
7. Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma.
Sengupta D; Kannan A; Kern M; Moreno MA; Vural E; Stack B; Suen JY; Tackett AJ; Gao L
Epigenetics; 2015; 10(6):460-6. PubMed ID: 25941994
[TBL] [Abstract][Full Text] [Related]
8. PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability.
Gryder BE; Yohe ME; Chou HC; Zhang X; Marques J; Wachtel M; Schaefer B; Sen N; Song Y; Gualtieri A; Pomella S; Rota R; Cleveland A; Wen X; Sindiri S; Wei JS; Barr FG; Das S; Andresson T; Guha R; Lal-Nag M; Ferrer M; Shern JF; Zhao K; Thomas CJ; Khan J
Cancer Discov; 2017 Aug; 7(8):884-899. PubMed ID: 28446439
[TBL] [Abstract][Full Text] [Related]
9. Dissecting super-enhancer driven transcriptional dependencies reveals novel therapeutic strategies and targets for group 3 subtype medulloblastoma.
Li M; Han Y; Wang C; Kang W; Jiang W; Zhang L; Tang Y
J Exp Clin Cancer Res; 2022 Oct; 41(1):311. PubMed ID: 36273157
[TBL] [Abstract][Full Text] [Related]
10. KDM5C-Mediated Recruitment of BRD4 to Chromatin Regulates Enhancer Activation and BET Inhibitor Sensitivity.
Qiang Y; Fan J; Xie C; Yan L; Song X; Zhang N; Lin Y; Xiong J; Zhang W; Liu Y; Wei L; Li Y; Chen S; Liang K; Li F
Cancer Res; 2024 Apr; 84(8):1252-1269. PubMed ID: 38285760
[TBL] [Abstract][Full Text] [Related]
11. BET Epigenetic Reader Proteins in Cardiovascular Transcriptional Programs.
Borck PC; Guo LW; Plutzky J
Circ Res; 2020 Apr; 126(9):1190-1208. PubMed ID: 32324495
[TBL] [Abstract][Full Text] [Related]
12. Impaired cell fate through gain-of-function mutations in a chromatin reader.
Wan L; Chong S; Xuan F; Liang A; Cui X; Gates L; Carroll TS; Li Y; Feng L; Chen G; Wang SP; Ortiz MV; Daley SK; Wang X; Xuan H; Kentsis A; Muir TW; Roeder RG; Li H; Li W; Tjian R; Wen H; Allis CD
Nature; 2020 Jan; 577(7788):121-126. PubMed ID: 31853060
[TBL] [Abstract][Full Text] [Related]
13. The ENL YEATS epigenetic reader domain critically links MLL-ENL to leukemic stem cell frequency in t(11;19) Leukemia.
Hu H; Saha N; Yang Y; Ahmad E; Lachowski L; Shrestha U; Premkumar V; Ropa J; Chen L; Teahan B; Grigsby S; Marschalek R; Nikolovska-Coleska Z; Muntean AG
Leukemia; 2023 Jan; 37(1):190-201. PubMed ID: 36435883
[TBL] [Abstract][Full Text] [Related]
14. Combined treatment with CBP and BET inhibitors reverses inadvertent activation of detrimental super enhancer programs in DIPG cells.
Wiese M; Hamdan FH; Kubiak K; Diederichs C; Gielen GH; Nussbaumer G; Carcaboso AM; Hulleman E; Johnsen SA; Kramm CM
Cell Death Dis; 2020 Aug; 11(8):673. PubMed ID: 32826850
[TBL] [Abstract][Full Text] [Related]
15. MYC activity at enhancers drives prognostic transcriptional programs through an epigenetic switch.
Jakobsen ST; Jensen RAM; Madsen MS; Ravnsborg T; Vaagenso CS; Siersbæk MS; Einarsson H; Andersson R; Jensen ON; Siersbæk R
Nat Genet; 2024 Apr; 56(4):663-674. PubMed ID: 38454021
[TBL] [Abstract][Full Text] [Related]
16. Transcription control by the ENL YEATS domain in acute leukaemia.
Erb MA; Scott TG; Li BE; Xie H; Paulk J; Seo HS; Souza A; Roberts JM; Dastjerdi S; Buckley DL; Sanjana NE; Shalem O; Nabet B; Zeid R; Offei-Addo NK; Dhe-Paganon S; Zhang F; Orkin SH; Winter GE; Bradner JE
Nature; 2017 Mar; 543(7644):270-274. PubMed ID: 28241139
[TBL] [Abstract][Full Text] [Related]
17. ENL: structure, function, and roles in hematopoiesis and acute myeloid leukemia.
Zhou J; Ng Y; Chng WJ
Cell Mol Life Sci; 2018 Nov; 75(21):3931-3941. PubMed ID: 30066088
[TBL] [Abstract][Full Text] [Related]
18. Selective inhibition of tumor oncogenes by disruption of super-enhancers.
Lovén J; Hoke HA; Lin CY; Lau A; Orlando DA; Vakoc CR; Bradner JE; Lee TI; Young RA
Cell; 2013 Apr; 153(2):320-34. PubMed ID: 23582323
[TBL] [Abstract][Full Text] [Related]
19. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
Faivre EJ; McDaniel KF; Albert DH; Mantena SR; Plotnik JP; Wilcox D; Zhang L; Bui MH; Sheppard GS; Wang L; Sehgal V; Lin X; Huang X; Lu X; Uziel T; Hessler P; Lam LT; Bellin RJ; Mehta G; Fidanze S; Pratt JK; Liu D; Hasvold LA; Sun C; Panchal SC; Nicolette JJ; Fossey SL; Park CH; Longenecker K; Bigelow L; Torrent M; Rosenberg SH; Kati WM; Shen Y
Nature; 2020 Feb; 578(7794):306-310. PubMed ID: 31969702
[TBL] [Abstract][Full Text] [Related]
20. A distal super-enhancer activates oncogenic ETS2 via recruiting MECOM in inflammatory bowel disease and colorectal cancer.
Chen Y; Ying Y; Wang M; Ma C; Jia M; Shi L; Wang S; Zheng X; Chen W; Shu XS
Cell Death Dis; 2023 Jan; 14(1):8. PubMed ID: 36609474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]